WO2001037779A3 - A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer - Google Patents

A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer Download PDF

Info

Publication number
WO2001037779A3
WO2001037779A3 PCT/US2000/032056 US0032056W WO0137779A3 WO 2001037779 A3 WO2001037779 A3 WO 2001037779A3 US 0032056 W US0032056 W US 0032056W WO 0137779 A3 WO0137779 A3 WO 0137779A3
Authority
WO
WIPO (PCT)
Prior art keywords
staging
diagnosing
imaging
monitoring
breast cancer
Prior art date
Application number
PCT/US2000/032056
Other languages
French (fr)
Other versions
WO2001037779A2 (en
Inventor
Susana Salceda
Robert Cafferkey
Herve Recipon
Yongming Sun
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Priority to EP00980657A priority Critical patent/EP1267934A4/en
Priority to JP2001539396A priority patent/JP2003526342A/en
Priority to CA002390802A priority patent/CA2390802A1/en
Publication of WO2001037779A2 publication Critical patent/WO2001037779A2/en
Publication of WO2001037779A3 publication Critical patent/WO2001037779A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.
PCT/US2000/032056 1999-11-23 2000-11-22 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer WO2001037779A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00980657A EP1267934A4 (en) 1999-11-23 2000-11-22 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
JP2001539396A JP2003526342A (en) 1999-11-23 2000-11-22 Novel methods of diagnosing, monitoring, staging, imaging and treating breast cancer
CA002390802A CA2390802A1 (en) 1999-11-23 2000-11-22 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16697399P 1999-11-23 1999-11-23
US60/166,973 1999-11-23

Publications (2)

Publication Number Publication Date
WO2001037779A2 WO2001037779A2 (en) 2001-05-31
WO2001037779A3 true WO2001037779A3 (en) 2002-03-21

Family

ID=22605420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032056 WO2001037779A2 (en) 1999-11-23 2000-11-22 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer

Country Status (4)

Country Link
EP (1) EP1267934A4 (en)
JP (1) JP2003526342A (en)
CA (1) CA2390802A1 (en)
WO (1) WO2001037779A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6780586B1 (en) 1999-11-29 2004-08-24 Protein Design Labs, Inc. Methods of diagnosing breast cancer
CA2392510A1 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU2003263767A1 (en) * 2002-07-03 2004-01-23 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033915A1 (en) * 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Breast cancer specific gene 1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
CA2347906A1 (en) * 1998-08-04 2000-02-17 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
AU3752700A (en) * 1999-03-15 2000-10-04 Eos Biotechnology, Inc. Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033915A1 (en) * 1997-02-03 1998-08-06 Human Genome Sciences, Inc. Breast cancer specific gene 1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEAULIEU M. ET AL.: "Isolation and characterization of a human orphan UDP-glucuronosyltransferase, UGT2b11", BIOCHEM. BIOPHYS. RES. COMM., vol. 248, 1998, pages 44 - 50, XP002947905 *
DATABASE GENBANK [online] 30 July 1997 (1997-07-30), BEAULIEU ET AL., XP002947907, accession no. EMBL Database accession no. AF016492 *
DATABASE GENBANK [online] 6 September 1999 (1999-09-06), MOMENI ET AL., XP002947906, accession no. EMBL Database accession no. AF183810 *
DATABASE SEPTREMBL [online] XP002947493, accession no. EMBL Database accession no. Q9UHF7 *
JANERICH D.T ET AL.: "Maternal pattern of reproduction and risk of breast cancer in daughters: Results from the Utah population database", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 86, no. 21, 2 November 1994 (1994-11-02), pages 1634 - 1639, XP002947904 *
MOMENI P. ET AL.: "Mutations in a new gene, encoding a zinc-finger protein, cause trichorhino-phalangeal syndrome type I", NATURE GENETICS, vol. 24, January 2000 (2000-01-01), pages 71 - 74, XP002947494 *

Also Published As

Publication number Publication date
EP1267934A2 (en) 2003-01-02
JP2003526342A (en) 2003-09-09
WO2001037779A2 (en) 2001-05-31
CA2390802A1 (en) 2001-05-31
EP1267934A4 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
EP2053129A8 (en) Method of diagnosing, monitoring, staging, imaging and treating various cancers
MXPA01008794A (en) Method of diagnosing and monitoring malignant breast carcinomas.
EP1105528A4 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
WO2001037779A3 (en) A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP1239874A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1080227A4 (en) A novel method of diagnosing, monitoring, and staging colon cancer
IL145669A0 (en) Single channel, single dilution detection method
WO2002040716A3 (en) Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
HK1032167A1 (en) Additional information embedding method, addition al information detecting method, additional information embedding apparatus and additional information detecting apparatus.
HK1031399A1 (en) Process for synthesizing cox-2 inhibitors.
EP1082459A4 (en) A novel method of diagnosing, monitoring, and staging lung cancer
ZA200006947B (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline.
AU2001251013A1 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001250932A1 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2002312445A1 (en) Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression
EP1131095A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer
WO2001072780A3 (en) Polynucleotides for diagnosing mammary gland cancer
AU2001241656A1 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
WO2003052121A3 (en) Method of reducing angiogenesis
EP1082460A4 (en) A novel method of diagnosing, monitoring, and staging prostate cancer
AU2001271621A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2002006515A3 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
EP1115426A4 (en) Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers and testicular cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2390802

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 539396

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000980657

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2000980657

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980657

Country of ref document: EP